1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Nanjing Vazyme Biotech Co., Ltd. Class A

Nanjing Vazyme Biotech Co., Ltd. Class A

SSSE:688105
21.09
CNY
-1.22
(-5.47%)
8.97BMarket Cap
Oct 29Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.24
0.33
0.52
3.38
3.96
6.88
2.51
2.93
2.55
- -
Basic EPS, GAAP
0.01
- -
0.05
1.78
1.44
1.15
-0.14
-0.04
-0.03
- -
Free Cash Flow per Basic Share
-0.05
-0.07
-0.01
1.41
0.75
-0.44
-0.16
-0.18
0.34
- -
Dividend per Share
- -
- -
- -
- -
0.01
0.26
1.04
0.17
0.14
0.4
Book Value per Share
0.32
0.35
0.43
2.85
7.94
8.86
7.75
7.55
7.34
6.98
Tangible Book Value per Share
0.32
0.35
0.42
2.83
7.9
8.52
7.3
7.12
6.92
6.58
Basic Weighted Avg Shares
468
520
520
462
472
518
512
470
540
524
Sales/Revenue/Turnover
112
171
268
1,564
1,869
3,569
1,286
1,378
1,378
- -
Operating Margin (%)
-0.15
2.01
10.2
65.37
42.62
34.66
-2.98
-4.03
-2.6
- -
Depreciation Expense
3
4
7
14
55
122
157
153
150
- -
Net Income, GAAP
4
1
26
822
678
594
-71
-18
-17
- -
Effective Tax Rate (%)
- -
- -
- -
14.34
11.27
2.61
- -
- -
- -
- -
Profit Margin (%)
3.24
0.61
9.61
52.52
36.3
16.65
-5.52
-1.31
-1.21
- -
Working Capital
108
96
125
1,145
3,664
3,411
2,711
2,668
2,666
2,530
LT Debt
- -
- -
- -
34
60
128
107
143
127
110
Total Equity
151
166
200
1,332
4,127
4,612
4,029
3,944
3,791
3,602
Return on Invested Capital (%)
- -
- -
- -
100.69
24.22
15.03
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
101.97
24.36
13.07
- -
- -
- -
- -
Return on Common Equity (%)
- -
0.66
14.09
107.25
24.85
13.6
-1.64
-0.45
-0.43
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
715
894
561
LT Borrowings
- -
- -
- -
LT Finance Leases
127
114
110
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
517
517
517
Market Capitalization
7,963
7,776
8,970

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,708
3,814
3,376
Cash, Cash Equivalents & STI
2,854
2,940
2,512
Accounts Receivable, Net
444
459
456
Inventories
344
352
350
Total Current Liabilities
1,042
1,126
846
Payables & Accruals
- -
- -
- -
ST Debt
715
894
561
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
40.58%
-3.86%
Free Cash Flow
- -
-117.67%
-319.64%
Net Income, GAAP
- -
-44.89%
-8.18%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
659.16%
-3.61%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
302
348
337
392
1,378
2025
285
321
- -
425
1,378
2026
321
380
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.02
- -
-0.07
-0.04
2025
- -
- -
- -
-0.04
-0.03
2026
0.01
0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.02
0.07
0.05
0.17
2025
0.01
0.13
- -
0.01
0.14
2026
0.01
0.39
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Lin Cao
Full Time Employees
3,002
Sector
Health technology
Industry
Biotechnology
Address
Building D2 Nanjing JS China 210033
IPO Date
Nov 15, 2021
Website
vazyme.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) develops, manufactures, and commercializes biotechnology products including enzymes, antigens, antibodies, biological reagents, nucleic acid extraction kits, PCR reagents, POCT diagnostic reagents, and instruments for life sciences, in vitro diagnostics, molecular biology, and biomedicine applications; offers solutions in cardiovascular and cerebrovascular diseases, inflammation, prepotency, gastric functions, autoimmunity, renal functions, chronic disease management, and respiratory diseases; and provides technical services such as antibody discovery. The company operates through three main segments covering research reagents, high-throughput sequencing reagents, experimental instruments and consumables, diagnostic materials, diagnostic reagents, pharmaceutical R&D reagents, GLP-1 polypeptide raw materials, and nucleic acid drug series, serving research institutions, diagnostics, pharmaceutical companies, and healthcare providers primarily in China with global presence in over 60 countries and regions. Founded in 2012 and headquartered in Nanjing, China, Vazyme recently established a strategic partnership and joint venture with Sinopep (688076.SH) in 2025 to advance synthetic biology applications in biopharmaceuticals, animal healthcare, and agriculture; and launched a global packaging upgrade for all product lines in July 2025.